The two clones differed with respect to the number of hTSHr expressed per cell (34,000 in JPO9 and 2,000 in JP26 cells). Both responded extremely well to bTSH, the cAMP response to 0.001 III/L. bTSH was distinguishable from basal values. Interestingly, JPO9 cells were readily stimulated by hCG (20-100 mg&; 0.52-2.6 x 10-s mol/L) to release CAMP, whereas JP26 cells showed little if any response. Also. CAMP stimulation ureduced bv asialo-hCG was la-fold in JPO9 cells'and only 4-fold in JP26 cells compared to 45-and 67-fold stimulations by bTSH, respectively. Stimulation by asialo-hCG was approximately 30% that of bTSH in JPO9 cells, but less than 6% in JP26 cells. When assessing the thyrotropic activity of the microheterogeneous isoforms of hCG, more alkaline p1 forms were found to be more active than those of a more acidic p1 regardless of whether they were derived from normal or molar pregnancy urine. Further studies with hCG, asialohCG, asialoagalacto-hCG, and deglycosylated hCG revealed that removal of sialic acid caused a marked increase in both its a&&y for hTSHr and its cAMPreleasing potency, whereas removal of further carbohydrate, although it slightly enhanced receptor binding, was detrimental to adenylate cyclase activation. In conclusion, differences in hTSHr expression may cause a variation in the CAMP response to hCG or its glycosylation variants, as does the microheterogeneity of the hormone itself. These mechanisms may be responsible at least in part for the divergent responses of different cell types to hCG and render interpretation of the physiological meaning of the data obtained in recombinant receptor systems difficult.
(J Clin Endocrinol Metab 80: [1605] [1606] [1607] [1608] [1609] [1610] 1995) h CG exhibits considerable homology in its structure with human TSH (hTSH) as does CG/LH receptor with TSH receptor (TSHr) (l-3). As a result, this hormone has been reported to possess significant thyrotropic activity, which may be clinically relevant in hyperthyroidism of pregnant women and patients with trophoblastic tumors (4). However, its role as a thyroid stimulator has been a subject of controversy, because in vitro studies have shown a wide variation in the thyroid response to hCG (5-12).
Therefore, to elucidate possible factors that may account for the variation observed in the in vitro thyroid response to hCG, we investigated the interaction of hCG with recombinant human TSHr (hTSHr) expressed in Chinese hamster ovary (CHO) cells. To study the variability related to hTSHr expression, we assessed ['?]bTSH binding inhibition and CAMP stimulation induced by bTSH and hCG in two different clones of CHOTSHr cells stably transfected with the hTSI-Ir. Further, to evaluate the variability related to the microheterogeneity of the hormone itself, we assessed the thyrotropic activities of naturally occurring isoforms of hCG derived from either normal or molar pregnancy urine. To more precisely define the role of carbohydrate in this respect, the glycosylation variants, asialohCG, asialoagalacto-hCG, and deglycosylated hCG, were also tested for their bTSH binding-inhibiting and cAMI'-stimulating activities in CHO-TSHr cells. 
Materials and Methods

Materials
Studies of binding to CHO-TSHr cells
To study the binding of '=I-labeled bTSH, cells were transferred to 24-well plates (-7 x lo5 cells/well) and incubated together with the tracer (-6,000 cpm; SA, 40,000-60,000 Ci/kg) and the respective cold ligands at 4 C for 24 h in modified sodium-free Hanks' buffer supplemented with 278 mmol/L sucrose and 0.1% BSA (11, 18) . At the end of the incubation period, the supematant was removed, the cells were washed and solubilized with 0.5 mL 1 N NaOH, and their '=I content was measured in a y-counter. (Fig. la) . The difference in the binding capacity of the clones was apparently related to the number of hTSHr expressed per cell, which was estimated to be 34,000 in JP09 and 2,000 in JP26 cells (Fig. la) . Basal CAMP activity and bTSH-stimulated CAMP production were higher in JP09 cells than in JP26 cells. The ratio of maximum bTSH stimulation to basal activity, however, was lower in JP09 than in JP26 cells Fig. lb) . The wild-type cells, as expected, were unresponsive to bTSH stimulation (data not shown).
Responses of the CHO-TSHr cell clones JPO9 and JP26 to hCG and asialo-hCG
We assessed the inhibition of ['251 ]bTSH binding to CHOTSHr JP09 and JP26 cells by hCG and asialo-hCG. Although hCG itself displayed little binding-inhibiting activity in either cell clone, asialo-hCG was much more potent in this respect; its ID,, was 20 mg/L (5.8 X 10e7 mol/L) in JP09 cells and 7 mg/L (2.0 X 10P7 mol/L) in JP26 cells (Fig. 2a) . With respect to CAMP activation, a significant (P < 0.01, combined data from three closely concurring experiments with triplicate determinations), although not very impressive, CAMP increase over basal values in response to hCG stimulation was observed in JP09 cells, whereas little if any stimulation was seen in JP26 cells (Fig. 2b) . The difference in the response of the two clones was more pronounced when cells were stimulated with asialo-hCG (Fig. 2b) . Asialo-hCG stimulated 
Thyrotropic activity of hCG isoforms in CHO-TSHr cells
Next, the in vitro thyrotropic potencies of hCG isoforms derived from pregnancy and molar hCG were assessed in CHO-TSHr JP09 cells. Pool II (~14.1-5) and pool III (p1 >5) derived from hCGp were more active than pool I (~13.9-4.1) of hCGp in terms of the ability to both inhibit ['2511bTSH binding and stimulate CAMP production (Fig. 3) . Similarly, in the pools obtained from hCGm, a more alkaline p1 was associated with increased thyrotropic activity (Fig. 3) . When comparing hCGp and hCGm, on the other hand, the presence of alkaline isoforms was about the same in the two preparations (Fig. 3, inset) , and the CAMP-stimulating activity in CHO-TSHr cells was also similar (data not shown). The corresponding pools derived from hCGp or hCGm also did not differ in potency to bind to and stimulate CAMP release from CHO-TSHr cells (Fig. 3) .
Role of carbohydrate in hCG for hTSHr binding and CAMP stimulation in CHO-TSHr cells
The immunological activities of hCG, asialo-hCG, asialoagalacto-hCG, and deglycosylated hCG preparations employed in these studies were assessed by a specific holo-hCG assay and found to be comparable (data not shown).
As shown earlier, hCG itself showed little ability to inhibit for the modified hormone, as judged from its ability to inhibit ['2511bTSH binding. Nearly totally deglycosylated hCG was intermediate to asialoagalacto-hCG and asialo-hCG in this respect (Fig. 4a) . With respect to the functional activation of hTSHr by these ligands, asialo-hCG was clearly the most potent form of hCG, although its potency, when tested in the same experiment, approached only approximately 30% the activity of bTSH (100 IU/L). Asialoagalacto-hCG and deglycosylated hCG, on the other hand, were considerably less active as stimulators of CAMP release in CHO-TSHr cells than asialo-hCG, but still more active than hCG itself, which was the least effective agent (Fig. 4b) .
Discussion
The occurrence of hyperthyroidism in patients with trophoblastic tumors and some cases of normal pregnancy may Removal of sialic acid from hCG markedly enhances both the affinity to hTSHr and the intrinsic activity of the hormone, whereas removal of further carbohydrates, although slightly favoring receptor binding, impairs receptor activation. At the maximum concentration tested (100 IU/L), bTSH released 1600 nmol/L CAMP (not shown). Eachpoint represents the mean of closely concurring duplicates for specific binding data and the mean -+ SD (n = 3) for CAMP determinations in a single experiment, and the results concur closely with those obtained in two other experiments.
be explained by stimulation of the thyroid gland by hCG, which is present in exceedingly high concentrations in the circulation of these patients; a distinct molecular variant form of hCG with increased thyrotropic activity produced by the trophoblastic tumor or during pregnancy; or a combination of the two factors (7). With respect to the in vitro thyrotropic activity of hCG, most investigators were unable to demonstrate significant stimulation of the CAMP response in human thyroid membranes (g-10,15). The same failure to stimulate CAMP activity in vitro has been observed in a human thyroid carcinoma cell line (HTC) expressing the recombinant hTSHr, but lacking endogenous hTSHr (11). In thyroid cells of rodent origin, on the other hand, including FRTL-5 cells and CHO cells transfected with the hTSHr, hCG has been shown to readily evoke significant CAMP responses (10, 18, (26) (27) (28) (29) (30) . Clearly, the discrepancies seemed too pronounced to be explained by the use of different assay conditions.
To seek possible explanations for the variation observed in the thyroid response to hCG, we studied two clones of CHO cells that had been stably transfected with hTSHr. Remark- The difference between the two cell clones in their response to asialo-hCG, which was a more potent stimulator of CHOTSHr cells than hCG, was even more striking. Interestingly, in our studies, the hCG responsiveness of the two CHO cell clones appeared not to parallel their bTSH sensitivity. This conclusion was further supported by the finding that CAMP production by asialo-hCG approached 30% that of bTSH in JP09 cells, but less than 6% that in JP26 cells. Both clones were extremely sensitive to stimulation by bTSH, with a response induced by a concentration as low as 0.001 IU/L (0.89 pmol/L) being readily distinguishable from basal activity. For comparison, in HTC-TSHr cells, the limit of detection was about 0.1 IU/L bTSH (11). The variation observed in the responses to the various stimulators of the two CHO cell clones expressing hTSHr was surprising. It may be accounted for by differences in the expression of hTSHr in the two clones. In this respect, the binding studies we conducted indicated a number of hTSHr per cell in the physiological range in JP26 cells, whereas hTSHr density in JP09 cells was more than 10 times higher than that in normal human thyrocytes (31). The possibility that CAMP stimulation was affected in part by a stimulation of endogenous hCG/LH receptors could be excluded, because CHO wild-type cells were not stimulated by hCG or asialo-hCG.
Another interesting aspect of the study relates to the role of carbohydrate in the thyrotropic activity of hCG in CHOTSHr cells, which was strikingly different from that previously reported in human assay systems. In human thyroid membranes or cells, including HTC cells expressing hTSHr (32), desialylated variants of hCG, although exhibiting markedly increased affinity for hTSHr, were devoid of intrinsic activity and acted as pure antagonists (11, 15, 17, 33, 34) . In contrast, in CHO-TSHr cells, desialylation of hCG resulted in a marked increase in both its affinity for hTSHr and its CAMP-stimulating activity. This was true for less sialylated isoforms of hCG and enzymatically desialylated hCG. Also, the effect was more pronounced in JP09 cells, which express an exceedingly high receptor density, than in JP26 cells. Cleavage of further carbohydrate, such as galactose, and removal of nearly the total carbohydrate moiety, on the other hand, although slightly improving receptor recognition, exerted a detrimental influence on intrinsic activity in JP09 cells, although asialoagalacto-hCG and deglycosylated hCG were still more active than hCG. Interestingly, JP09 cells closely resemble FRTL-5 cells in this respect, which we have previously shown to be stimulated by desialylated hCG variants (18).
Consistent with these findings, the rodent thyroid has long been recognized to be more sensitive to stimulation by hCG and desialylated hCG than the human thyroid (10, 26). Apparently, the role of carbohydrate in signal transduction varies among cells that differentially express TSHr or different types of cells expressing TSHr. This may explain at least in part the divergent responses to carbohydrate-modified hCG forms observed in various cell lines. As for the CHO cells expressing hTSHr, although they provide one of the most sensitive tools currently available for measuring thyroid stimulators, their nonthyroid nonhuman descent and the supraphysiological hTSHr number expressed emphasize the fact that any conclusions about the physiological significance of the findings derived from CHO cells should be drawn with caution. For that reason, at the present time it is not possible to resolve, on the basis of these studies, the ongoing controversy of whether hCG is indeed a thyroid stimulator of significant potency in man. The present findings provide a strong support in favor of the use of human thyroid cell lines, such as HTC, for hTSHr expression studies.
With respect to the existence of molecular forms of hCG with increased thyrotropic activity, the present study revealed a variation in thyrotropic activity among the microheterogeneous isoforms of hCG (35, 36) . It is important to note that this study, unlike previous studies by Pekary et al. (37) and Yoshimura et al. (381, focused on the isohormones of hCG and did not include variant forms of hCG or fragments thereof, which are known to be present in pregnancy urine or placental tissue extracts. These researchers reported an increased in vitro thyrotropic activity of partially sialated hCG variants extracted from hydatidiform moles of hyperthyroid patients (37). In contrast to their material, our molar hCG was derived from euthyroid patients. The present studies revealed a relation between the p1 value of the hCG molecules and their thyrotropic activity in CHO-TSHr JP09 cells, with alkaline isoforms displaying an enhanced potency. This was true for hCG of both pregnancy and molar origin. On the other hand, we found no major differences between the activities of molar hCG and pregnancy hCG or between the isoforms of identical p1 derived from hCGp or hCGm. We conclude that, apart from tumor-derived hCG variants, which may be either highly acidic or basic forms of hCG (37-39), the hCG molecule itself is made up of isohormones that differ in their thyrotropic activity, and even subtle changes in the p1 spectrum of hCG may affect its thyrotropic activity.
In conclusion, both the differential expression of hTSHr and the intrinsic microheterogeneity of the hormone cause a variation in the CAMP response to hCG in CHO-TSHr cells. Both mechanisms may at least in part explain previous observations that the hCG response differs among thyroid cells, particularly when they are derived from different species, and that the correlation between serum hCG concentrations and thyroid hormone levels in patients with trophoblast disease has been generally found to be poor (10, (39) (40) (41) (42) . They may also play a role in modulating the thyroid response to hCG during pregnancy or trophoblast disease. 
